Skip to main content
Clinical Trials/SLCTR/2019/037
SLCTR/2019/037
Completed
Phase 2

Efficacy and Safety of Eltrombopag to correct thrombocytopenia in moderate to severe dengue patients- a Phase II Randomized Clinical Controlled Trial

Incepta Pharmaceuticals Ltd.0 sites100 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Dengue Fever (DF), Dengue Haemorregic Fever (DHF) and Dengue Shock Syndrome (DSS)
Sponsor
Incepta Pharmaceuticals Ltd.
Enrollment
100
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • a. Age: More than 15 years and less than 65 years
  • b. NS1 positivity within 4 days and or /(IgM or IgG) positive after 7 days
  • c. Platelet count: below 1,00,000/mm3

Exclusion Criteria

  • a. Known Pregnancy.
  • b. Thrombocytopenia caused by other factor such as Severe Aplastic Anemia (SAA), Chronic
  • Liver Disease (CLD) and Immune\- thrombocytopenia (ITP).
  • c. ALT/AST levels higher than 5 times of upper normal limit.
  • d. History of portal vein thrombosis.
  • e. Patients infected with HCV, HBV, chronic liver disease (Drug induced, alcohol induced).
  • f. Patients with any history of receiving immunosuppressive therapy.
  • g. Patients with any severe co\-morbidity.

Outcomes

Primary Outcomes

Not specified

Similar Trials